Table 2.

Cox univariate and multivariate analysis for disease free survival in the 278 premenopausal breast cancer patients

	Patients		Univariate analysis			Multivariate analysis
Factor of base model	Number	Percent	HR	95 percent CI	P value	HR	95 percent CI	P value
Age (years)
<39	54	24	1.00			1.00
40–49	167	60	0.72	0.50–1.06		0.66	0.44–0.98
50–59	57	21	0.42	0.23–0.77	0.013	0.35	0.19–0.67	<0.001
Nodal status
Negative	134	48	1.00			1.00
Positive	144	52	1.90	1.34–2.70	<0.001	3.68	2.11–6.42	<0.001
Histological grade
Poor	153	55	1.00			1.00
Unknown	59	21	0.51	0.32–0.83		0.54	0.33–0.88
Well/moderate	66	24	0.55	0.36–0.85	0.002	0.56	0.35–0.88	0.019
Tumor size
≤2 cm	113	41	1.00			1.00
>2 cm	165	59	1.77	1.23–2.54	0.002	1.57	1.07–2.30	0.021
Estrogen receptor status
Negative	78	28	1.00			1.00
Positive	200	72	0.87	0.60–1.27	0.48	1.01	0.68–1.49	0.96
Adjuvant therapy
No	158	57	1.00			1.00
Yesa	120	43	1.41	1.01–1.97	0.045	0.41	0.24–0.70	0.001
Factors analyzed
Carriership
Non-carriersb			1.00			1.00
GnRH 16Ser	121	44	1.40	1.00–1.96	0.050	1.32	0.93–1.88	0.12
LHR insLQ	131	47	1.59	1.14–2.23	0.007	1.64	1.16–2.32	0.005
Combined carriership
Non-carriers	87	31	1.00			1.00
Only GnRH 16Ser	60	22	1.39	0.84–2.29	0.19	1.24	0.74–2.08	0.42
Only LHR insLQ	70	25	1.59	0.99–2.54	0.055	1.56	0.97–2.51	0.067
LHR insLQ+GnRH16Ser	61	22	2.17	1.36–3.48	0.001	2.14	1.32–3.45	0.002

^aOf 120 patients who received adjuvant therapy, 110 received chemotherapy (mainly CMF, n = 101), 4 endocrine therapy, and 6 both; node negatives were not treated. ^bThe number of GnRH 16Ser non-carriers was 157, and of LHR insLQ non-carriers was 147 patients.